Skip to main content

Advertisement

Log in

BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma—an Indian study

Tumor Biology

Abstract

Mounting evidences suggest that aberrant methylation of CpG islands is a major pathway leading to the inactivation of tumour suppressor genes and the development of cancer. The aim of the current study was to examine the prevalence of the promoter hypermethylation and protein expression of the BRCA1 gene in epithelial ovarian carcinoma (EOC) to understand the role of epigenetic silencing in ovarian carcinogenesis. We studied the promoter methylation of the BRCA1 gene by methylation-specific PCR in a cohort of 88 patients with EOC, 14 low malignant potential (LMP) tumours and 20 patients with benign tumours of the ovary. The expression of the BRCA1 protein by immunohistochemical analysis was carried out in a subset of 64 EOCs, 10 LMP tumours, 10 benign tumours and 5 normal ovarian tissues. The frequencies of methylation in EOCs and LMP tumours were 51.2 and 57 %, respectively, significantly higher (p = 0.000 and p = 0.001) in comparison to benign tumours and normal ovarian tissue where no methylation was seen. Expression of BRCA1 was significantly lower in EOCs (p = 0.003). Lack of protein expression correlated with tumour grade and type. The methylation status correlated well with downregulation of BRCA1 expression. Our results clearly demonstrate that hypermethylation of BRCA1 promoter is a frequent event in ovarian cancer. These data support the hypothesis that BRCA1 promoter methylation plays an important role in the functional inactivation of BRCA1. Follow-up clinical data will reveal the impact of BRCA1 methylation on survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. C A Cancer J Clin. 2001;51:15–36.

    Article  CAS  Google Scholar 

  2. Cannistra SA. Cancer of the ovary. N Engl J Med. 1993;329:1550–9.

    Article  CAS  PubMed  Google Scholar 

  3. Link Jr CJ, Reed E, Kohn EC, Sarosy G. Borderline ovarian tumors. Am J Med. 1996;101:217–25.

    Article  PubMed  Google Scholar 

  4. Scully RE. WHO classification and nomenclature of ovarian cancer. J Natl Cancer Inst Monogr. 1975;42:5–7.

    CAS  Google Scholar 

  5. Cliby W, Ritland S, Hartmann L, et al. Human epithelial ovarian cancer allelotype. Cancer Res. 1993;53:2393–8.

    CAS  PubMed  Google Scholar 

  6. Sato T, Saito H, Morita R, et al. Allelotype of human ovarian cancer. Cancer Res. 1991;51:5118–22.

    CAS  PubMed  Google Scholar 

  7. Bird A, Wolffe AP. Methylation-induced repression—belts, braces and chromatin. Cell. 1999;99:451–4.

    Article  CAS  PubMed  Google Scholar 

  8. Wei SH, Chen CM, Strathdee G, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res. 2002;8:2246–52.

    CAS  PubMed  Google Scholar 

  9. Pérez-Vallés A, Martorell-Cebollada M, Fuster-Diana E, García-García JA, Nogueira-Vázquez E. The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study. J Clin Pathol. 2001;54:476–80.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95:866–71.

    Article  CAS  PubMed  Google Scholar 

  11. Jazaeri AA, Yee CJ, Sotiriou C, et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst. 2002;94:990–1000.

    Article  CAS  PubMed  Google Scholar 

  12. Bozzetti C, Bortesi B, Merisio C. Loss of heterozygosity (LOH) in ovarian cancer. Int J Gynaecol Obstet. 2004;85:294–5.

    Article  CAS  PubMed  Google Scholar 

  13. Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene. 1998;17:1807–12.

    Article  CAS  PubMed  Google Scholar 

  14. Weberpals JI, Tu D, Squire JA, Pelletier LB, Amin MS, Islam S, et al. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol. 2011;22(11):2403–10.

    Article  CAS  PubMed  Google Scholar 

  15. Xu CF, Brown MA, Chambers JA, Griffiths B, Nicolai H, et al. Distinct transcription start sites generate two forms of BRCA1 mRNA. Hum Mol Genet. 1995;4:2259–64.

    Article  CAS  PubMed  Google Scholar 

  16. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.

    CAS  PubMed  Google Scholar 

  17. Berger J, Daxenbichler G. DNA methylation of nuclear receptor genes—possible role in malignancy. J Steroid Biochem. 2002;80:1–11.

    Article  CAS  Google Scholar 

  18. Miranda TB, Jones PA. DNA methylation: the nuts and bolts of repression. J Cell Physiol. 2007;213(2):384–90.

    Article  CAS  PubMed  Google Scholar 

  19. Bianco T, Chenevix TG, Cooper JE, Dobrovic A, Walsh DC. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis. 2000;21(2):147–51.

    Article  CAS  PubMed  Google Scholar 

  20. Baldwin RL, Nemeth E, Cass I, Karlan BY, Narod S, Shvartsman H, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000;60:5329–33.

    CAS  PubMed  Google Scholar 

  21. Esteller M, Silva JM, Bonilla F, Dominguez G, Lerma E, Matias-Guiu X, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564–9.

    Article  CAS  PubMed  Google Scholar 

  22. Dhillon VS, Aslam M, Husain SA. The contribution of genetic and epigenetic changes in granulosa cell tumors of ovarian origin. Clin Cancer Res. 2004;10:5537–45.

    Article  CAS  PubMed  Google Scholar 

  23. Wiley A, Katsaros D, Beeghly A, Chen H, Puopolo M, Rigault de la Longrais IA, et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer. 2006;107:299–308.

    Article  CAS  PubMed  Google Scholar 

  24. Mancini DN, Rodenhiser DI, Ainsworth PJ, et al. CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene. 1998;16(9):1161–9.

    Article  CAS  PubMed  Google Scholar 

  25. Jiaze A, Qingyi W, Gordon BM, Karen HL, Li-E W, Xi C, et al. Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer—a case–control analysis. Int J Mol Epidemiol Genet. 2010;1(1):1–10.

    Google Scholar 

  26. Chan QK, Khoo US, Chan KY, et al. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res. 2005;11:2156–62.

    Article  Google Scholar 

  27. Pan Y, Wu Y, Zhu X, Shi Y. Methylation of tumor suppressor gene RASSF1A and BRCA1 in primary epithelial ovarian cancer. Sci Res Essays. 2010;5(24):3939–44.

    Google Scholar 

  28. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss has distinct molecular abnormalities. BMC Cancer. 2008;8:17.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Wang C, Horiuchi A, Imai T, et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol. 2004;202(2):215–23.

    Article  CAS  PubMed  Google Scholar 

  30. Wilcox CB, Baysal BE, DeLoia JA, Gallion HH, Strange MA. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet. 2005;159(2):114–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Dr Sanjay Navani for helping in construction of tissue microarray. We also thank Mr Prashant and Mr Shivshankar for their help in immunohistochemical staining of tissue microarray slides. We are grateful to Dr V Shanmugam (Research Assistant, NIMHANS) for helping with the statistical analysis.

Source of financial support

This study was not supported by any funding agency.

Conflicts of interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lakshmi Krishnamoorthy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shilpa, V., Bhagat, R., Premalata, C.S. et al. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma—an Indian study. Tumor Biol. 35, 4277–4284 (2014). https://doi.org/10.1007/s13277-013-1558-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1558-5

Keywords

Navigation